Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: c5research

23-HVI-4172009 CQD 650×450-2
August 29, 2023/Heart, Vascular and Thoracic/Research

Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

20-HVI-2013056-omega-3-pills_650x450
November 18, 2020/Heart, Vascular and Thoracic/Research

STRENGTH Results Prompt Questions About Omega-3 and Cardiovascular Risk

High-dose omega-3 fatty acid conferred no outcomes benefit over corn oil in high-risk patients

20-HVI-1915480-CQD-Ramping-up-research-after-COVID
August 6, 2020/COVID-19

Reigniting Clinical Research in the Wake of a Pandemic

Perspectives and learnings from our Heart, Vascular & Thoracic Institute

nurse-chat_650x450
October 30, 2018/Heart, Vascular and Thoracic/Insight & Perspectives

Advice for Getting a Start (or Upping Your Game) in Clinical Research

Q&A with the director of our Center for Clinical Research and C5Research group

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

650×450-Abazeed-Main
March 11, 2018/Heart, Vascular and Thoracic/Research

Genetic Analysis of Evacetrapib Outcomes Fails to Confirm Findings with Dalcetrapib

Potential of CETP inhibitors in patients with AA genotype must await outcome trial

17-HRT-3903-PRECISION-ABPM-CQD
August 29, 2017/Geriatrics

PRECISION-ABPM Reveals Differential Blood Pressure Effects with Chronic Use of 3 NSAIDs

Celecoxib has least impact, followed by naproxen and ibuprofen

15-RHE-961-Husni-Hero-Image-690x380pxl
August 29, 2017/Heart, Vascular and Thoracic/Research

CETP Inhibitor Evacetrapib’s Disappointments Extend to Diabetics Too

ACCELERATE substudy shows no benefit of evacetrapib in patients with diabetes

17-HRT-283-Cremer-ACC-CQD-650p
March 18, 2017/Heart, Vascular and Thoracic/Research

New PARTNER 2A Insights: Worsened RV Function and Tricuspid Regurgitation More Common with SAVR Vs. TAVR

But no difference in survival if there is no dysfunction

16-hrt-2353-nicholls-milano-cqd
November 16, 2016/Heart, Vascular and Thoracic/Research

MILANO-PILOT Brings ApoA-1 Milano Hopes to an End

Once-promising HDL-targeted therapy fails to show plaque regression

Ketamine Vs. ECT: $11.8M Grant Helps Size Them Up for Treatment-Resistant Depression
October 27, 2016/Behavioral Health

Ketamine vs. ECT: $11.8M Grant Helps Size Them Up for Treatment-Resistant Depression

Cleveland Clinic to lead four-center, 400-patient randomized trial

BackPage 1 of 2Next

Advertisement

Ad